Cost-effectiveness evaluation of linezolid, vancomycin and teicoplanin in treating nosocomial pneumonia caused by methicilin resistant staphylococcus aureus (mrsa) – Private health care system perspective
Abstract
Authors
R.K. Fujii P. Hájek G.D.A. Lanzara D.F. Manfrin J. Mould